Zhi Tong Cai Jing·2025-12-24 13:56Core Viewpoint - Sanofi has agreed to acquire Dynavax Technologies for approximately $2.2 billion to expand its vaccine product line, primarily focused on flu vaccines, with a cash offer of $15.50 per share, representing a 39% premium over Dynavax's closing price on Tuesday [1] Group 1: Acquisition Details - The acquisition price is set at about $2.2 billion [1] - Sanofi will pay $15.50 in cash per share for Dynavax, which is a 39% premium over the previous closing price [1] Group 2: Strategic Implications - This acquisition will allow Sanofi to gain access to an already marketed hepatitis B vaccine and an experimental shingles vaccine currently in early human trials [1] - The move is aimed at strengthening Sanofi's market position in the adult vaccination sector, complementing its existing vaccine portfolio that includes flu, respiratory syncytial virus, meningitis, and whooping cough vaccines [1]